Status:
COMPLETED
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients
Lead Sponsor:
Yonsei University
Conditions:
Non -Small Cell Lung Cancer
Eligibility:
All Genders
20+ years
Brief Summary
The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during niv...
Detailed Description
Non-small cell lung cancer (NSCLC) is the leading cause of cancer related mortality worldwide. Immune checkpoint blockade has emerged as a promising treatment modality in NSCLC. More recently, Program...
Eligibility Criteria
Inclusion
- Age≥ 18 years old.
- Histologically confirmed advanced NSCLC
- Metastatic or recurrent stage
- Failed to previous platinum based chemotherapy
- Performance status of Eastern Cooperative Oncology Group 0 to 1.
- Adequate organ function
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria.
Exclusion
- Symptomatic or uncontrolled brain metastasis
- History of autoimmune disease
- Other primary cancer within 3 years
Key Trial Info
Start Date :
February 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 7 2020
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03486119
Start Date
February 5 2018
End Date
July 7 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Yonsei University College of Medicine
Seoul, Korea, South Korea, 03722